相关实验视频

Updated: Jul 1, 2025

Assaying the Kinase Activity of LRRK2 in vitro

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

G2019S选择性LRRK2激酶抑制剂废除了线粒体DNA损伤

Nicholas Pena^1,2, Tara Richbourg^1,2, Claudia P Gonzalez-Hunt^1,2

¹Departments of Neurology and Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.

NPJ Parkinson's disease

|March 1, 2024

概括

帕金森病 (PD) 与LRRK2突变相关. 一种G2019S突变选择性抑制剂逆转了线粒体DNA损伤,显示了PD精准医学的潜力.

科学领域:

神经科学是一个神经科学.
遗传学遗传学是一种遗传学.
药理学药理学是指药理学的学科.

背景情况:

富含白素的重复激酶2 (LRRK2) 的致病突变是帕金森病 (PD) 的常见原因.
最常见的突变G2019S LRRK2变异导致激酶活性升高,并与线粒体DNA (mtDNA) 损伤有关.
LRRK2激酶抑制剂正在为PD治疗进行临床研究.

研究的目的:

评估G2019S突变选择性LRRK2抑制剂与非选择性抑制剂在逆转mtDNA损伤方面的疗效.
通过针对特定的突变活性的LRRK2 G2019S PD,探索精准医学方法的潜力.

主要方法:

使用了一种G2019S突变选择性抑制剂 (EB-42168) 和一种非选择性抑制剂 (MLi-2).
通过量化西部免疫块分析,通过测量LRRK2在Ser935/Ser1292的酸化来评估LRRK2激酶抑制.
在细胞模型和患者细胞中使用Mito DNA_DX试验量化mtDNA损伤.

主要成果:

EB-42168选择性地抑制了G2019S LRRK2的酸化,而MLi-2则抑制了野生型和G2019S LRRK2的酸化.
用EB-42168的急性治疗减少了LRRK2酸化,并恢复了mtDNA损伤到健康的对照水平.
在抑制剂洗后2小时内,mtDNA损伤水平动态恢复到基线,并且因酶抑制不能挽救髓性缺陷.

结论:

一种G2019S突变选择性LRRK2抑制剂在相关模型中有效逆转mtDNA损伤,证明了对LRRK2 G2019S PD的精密药物的潜力.
在小分子开发和临床试验中,mtDNA损伤可以作为药理动力学生物标志物来评估LRRK2激酶活性.

更多相关视频

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Animal Mitochondrial Genetics

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...